Reuters logo
French drugs agency suspends new Carmat artificial heart implants
November 30, 2016 / 5:30 PM / a year ago

French drugs agency suspends new Carmat artificial heart implants

PARIS (Reuters) - France’s national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

A spokeswoman said that the agency had requested further information from the company following the patients death, which was first reported by Europe 1 radio. The company was not immediately available for comment.

Carmat has not generated any significant revenue but is closely followed by investors as heart diseases represent a leading cause of death worldwide and its devices could represent a major medical breakthrough if proven reliable.

Reporting by Chine Labbe, writing by Leigh Thomas, Editing by Matthias Blamont

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below